TherapeuticsMD Inc. (TXMD)

4.87
NASDAQ : Health Technology
Prev Close 5.10
Day Low/High 4.87 / 5.25
52 Wk Low/High 4.30 / 7.66
Avg Volume 2.81M
Exchange NASDAQ
Shares Outstanding 237.88M
Market Cap 1.21B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TherapeuticsMD To Report Third Quarter 2018 Financial Results On November 7, 2018

TherapeuticsMD To Report Third Quarter 2018 Financial Results On November 7, 2018

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018, after the closing of the U.

TherapeuticsMD Announces FDA Approval Of TX-001HR: BIJUVA™ (Estradiol And Progesterone) Capsules For The Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause

TherapeuticsMD Announces FDA Approval Of TX-001HR: BIJUVA™ (Estradiol And Progesterone) Capsules For The Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only...

Interesting TXMD Put And Call Options For June 2019

Interesting TXMD Put And Call Options For June 2019

Investors in TherapeuticsMD Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

JetBlue, BlackRock, United Continental: 'Mad Money' Lightning Round

JetBlue, BlackRock, United Continental: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at JetBlue Airways, BlackRock, United Continental, Kratos Defense & Security, Energy Transfer Partners, TherapeuticsMD.

The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

Panic is not an investment strategy, says Jim Cramer. But when everyone else is panicking, that's when you need to buy.

Dell Technologies, Vail Resorts, Mastercard: 'Mad Money' Lightning Round

Dell Technologies, Vail Resorts, Mastercard: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dell Technologies, Vail Resorts, Mastercard, CyberArk, iRobot, Marriott Vacations, TherapeuticsMD, Edwards Lifesciences.

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

Jim Cramer says the president's predictability on trade makes it clear: Good news for the U.S. economy has become bad news for stocks.

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Jim Cramer weighs in on Urban Outfitters, CenturyLink, Avnet, Pitney Bowes, UnitedHealth Group, General Mills, TherapeuticsMD and more.

TherapeuticsMD Announces Multiple Presentations Related To Imvexxy™ And TX-001HR At The 2018 Annual Meeting Of The North American Menopause Society

TherapeuticsMD Announces Multiple Presentations Related To Imvexxy™ And TX-001HR At The 2018 Annual Meeting Of The North American Menopause Society

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the schedule of ten oral presentations and posters at NAMS 2018, the annual meeting of the North American Menopause Society being held in San Diego, California...

TherapeuticsMD Enters Into Label Discussions For TX-001HR

TherapeuticsMD Enters Into Label Discussions For TX-001HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the Company has entered into discussions with the U.

First Week Of November 16th Options Trading For TherapeuticsMD (TXMD)

First Week Of November 16th Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD To Present At 2018 Cantor Global Healthcare Conference

TherapeuticsMD To Present At 2018 Cantor Global Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in the 2018 Cantor Global Healthcare Conference being held on October 1-3, 2018.

TherapeuticsMD Announces The FDA Has Granted AnnoveraTM Marketing Exclusivity As A New Chemical Entity

TherapeuticsMD Announces The FDA Has Granted AnnoveraTM Marketing Exclusivity As A New Chemical Entity

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that Annovera TM (segesterone acetate and ethinyl estradiol vaginal system) has been granted marketing exclusivity as a new chemical entity (NCE) from the U.

First Week Of January 2021 Options Trading For TherapeuticsMD (TXMD)

First Week Of January 2021 Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options become available this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TherapeuticsMD Announces Commercial Availability Of Imvexxy™ 4 Mcg

TherapeuticsMD Announces Commercial Availability Of Imvexxy™ 4 Mcg

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States.

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will present at the 13 th Annual Wells Fargo Securities Healthcare Conference being held on September 5-6, 2018 in Boston.

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the United States (U.

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.

TherapeuticsMD Announces Pricing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering For Aggregate Gross Proceeds Of $85 Million

TherapeuticsMD Announces Pricing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering For Aggregate Gross Proceeds Of $85 Million

TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.

TherapeuticsMD Licenses Population Council's Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System

TherapeuticsMD Licenses Population Council's Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it has entered into an exclusive license agreement with the Population Council to commercialize its investigational segesterone acetate/ ethinyl estradiol...

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics Inc. (TSX: GUD) (" Knight"), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc.

TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering And Concurrent $20 Million Registered Direct Offering Of Common Stock

TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering And Concurrent $20 Million Registered Direct Offering Of Common Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of a $65 million underwritten public offering and a concurrent $20 million registered direct offering to a strategic investor of shares of its common stock.

TherapeuticsMD Announces Second Quarter 2018 Financial Results

TherapeuticsMD Announces Second Quarter 2018 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended June 30, 2018.

TherapeuticsMD To Report Second Quarter 2018 Financial Results On July 30, 2018

TherapeuticsMD To Report Second Quarter 2018 Financial Results On July 30, 2018

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its second quarter 2018 financial results on Monday, July 30, 2018, before the opening of the U.

A Very Odd Day for the Market

For the Russell to be down over one percent and breadth to be negative by 100 issues is highly unusual.

Interesting TXMD Put And Call Options For October 19th

Interesting TXMD Put And Call Options For October 19th

Investors in TherapeuticsMD Inc saw new options begin trading today, for the October 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 91 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of TXMD August 17th Options Trading

First Week Of TXMD August 17th Options Trading

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Draw Down Of $75 Million Under Term Loan With MidCap Financial

TherapeuticsMD Announces Draw Down Of $75 Million Under Term Loan With MidCap Financial

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company has completed the first draw down of $75 million under its previously announced $200 million term loan facility with MidCap Financial, managed...

TheStreet Quant Rating: D (Sell)